Arama Sonuçları - Mark S. Berger

  • Gösterilen 1 - 9 sonuçlar arası kayıtlar. 9
Sonuçları Daraltın
  1. 1
    A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma

    A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma Yazar: André Goy, Francisco J. Hernandez-Ilzaliturri, Brad S. Kahl, Peggy Ford, Ewelina Protomastro, Mark S. Berger

    Baskı/Yayın Bilgisi 2014
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  2. 2
    Daratumumab- <sup>225</sup> Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors

    Daratumumab- <sup>225</sup> Actinium conjugate demonstrates greatly enhanced antitumor activity against experimental multiple myeloma tumors Yazar: Wojciech Dawicki, Kevin J. Allen, Rubin Jiao, Mackenzie E. Malo, Muath Helal, Mark S. Berger, Dale L. Ludwig, Ekaterina Dadachova

    Baskı/Yayın Bilgisi 2019
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  3. 3
    Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma

    Phase I Dose Finding Studies of Obatoclax (GX15-070), a Small Molecule Pan-BCL-2 Family Antagonist, in Patients with Advanced Solid Tumors or Lymphoma Yazar: Jimmy J. Hwang, John Kuruvilla, David S. Mendelson, Michael J. Pishvaian, John F. Deeken, Lillian L. Siu, Mark S. Berger, Jean Viallet, John L. Marshall

    Baskı/Yayın Bilgisi 2010
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  4. 4
    Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin

    Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin Yazar: Michael Linenberger, Tom C. Hong, David Flowers, Eric L. Sievers, Ted Gooley, John M. Bennett, Mark S. Berger, Lance Leopold, Frederick R. Appelbaum, Irwin D. Bernstein

    Baskı/Yayın Bilgisi 2001
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  5. 5
    Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer

    Efficacy and Safety of Lapatinib As First-Line Therapy for ErbB2-Amplified Locally Advanced or Metastatic Breast Cancer Yazar: Henry Gómez, Dinesh Chandra Doval, Miguel A. Chavez, Peter Ang, Zeba Aziz, Shona Nag, Christina Ng, Sandra Franco, Louis W.C. Chow, Michael Arbushites, Michelle Casey, Mark S. Berger, Steven H. Stein, George W. Sledge

    Baskı/Yayın Bilgisi 2008
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  6. 6
    Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer

    Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer Yazar: Charles E. Geyer, John Forster, Deborah Lindquist, Stephen Chan, C. Gilles Romieu, Tadeusz Pieńkowski, Agnieszka Jagiełło-Gruszfeld, John Crown, Arlene Chan, Bella Kaufman, Dimosthenis Skarlos, Mario Campone, Neville Davidson, Mark S. Berger, Cristina Oliva, Stephen D. Rubin, Steven Stein, David Cameron

    Baskı/Yayın Bilgisi 2006
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  7. 7
    A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies

    A Phase I Study of the Pan Bcl-2 Family Inhibitor Obatoclax Mesylate in Patients with Advanced Hematologic Malignancies Yazar: Aaron D. Schimmer, Susan O’Brien, Hagop M. Kantarjian, Joseph Brandwein, Bruce D. Cheson, Mark D. Minden, Karen Yee, Farhad Ravandi, Francis J. Giles, Andre C. Schuh, Vikas Gupta, Michael Andreeff, Charles Koller, Hong Chang, Suzanne Kamel‐Reid, Mark S. Berger, Jean Viallet, Gautam Borthakur

    Baskı/Yayın Bilgisi 2008
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  8. 8
    Single-cell transcriptional diversity is a hallmark of developmental potential

    Single-cell transcriptional diversity is a hallmark of developmental potential Yazar: Gunsagar S. Gulati, Shaheen S. Sikandar, Daniel J. Wesche, Anoop Manjunath, Anjan Bharadwaj, Mark J. Berger, Francisco Ilagan, Angera H. Kuo, Robert W. Hsieh, Shang Cai, Maider Zabala, Ferenc A. Scheeren, Neethan A. Lobo, Dalong Qian, Feiqiao Brian Yu, Frederick M. Dirbas, Michael F. Clarke, Aaron M. Newman

    Baskı/Yayın Bilgisi 2020
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  9. 9
    Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10

    Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10 Yazar: Alexandra Zanin‐Zhorov, Jonathan M. Weiss, Alissa Trzeciak, Wei Chen, Jingya Zhang, Melanie S. Nyuydzefe, Carmen Arencibia, Seetharam Polimera, Olivier Schueller, Judilyn Fuentes‐Duculan, Kathleen M. Bonifacio, Norma Kunjravia, Inna Cueto, Jennifer Soung, Roy Fleischmann, Alan Kivitz, Mark Lebwohl, Margarita Núñez, Johnnie Woodson, Shondra Smith, Robert F. West, Mark S. Berger, James G. Krueger, John L. Ryan, Samuel D. Waksal

    Baskı/Yayın Bilgisi 2017
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:

Arama Araçları: